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Summary Fluctuation analysis experiments were performed to assess whether selection or induction determines expression of P-
glycoprotein and resistance in the murine Ehrlich ascites tumour cell line (EHR2) after exposure to daunorubicin. Thirteen expanded
populations of EHR2 cells were exposed to daunorubicin 7.5 x 10`8 M or 10-8 M for 2 weeks. Surviving clones were scored and propagated.
Only clones exposed to daunorubicin 7.5 x 10-9 M could be expanded for investigation. Drug resistance was assessed by the tetrazolium dye
(MTT) cytotoxicity assay. Westem blot was used for determination of P-glycoprotein. Compared with EHR2, the variant cells were 2.5- to 5.2-
fold resistant to daunorubicin (mean 3.6-fold). P-glycoprotein was significantty increased in 11 of 25 clones (44%). Analysis of variance
supported the hypothesis that spontaneous mutations conferred drug resistance in EHR2 cells exposed to daunorubicin 7.5 x 10-9 M. At this
level (5 log cell killing) of drug exposure, the mutation rate was estimated at 4.1 x 10-6 per cell generation. In contrast, induction seemed to
determine resistance in EHR2 cells in vitro exposed to daunorubicin 10-8 M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin
for 24 h. Aftertreatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (12-fold),
suggesting that in EHR2/0.8/R the mdrl gene was activated by induction. In conclusion, our study demonstrates that P-glycoprotein
expression and daunorubicin resistance are primarily acquired by selection of spontaneously arising mutants. However, under certain
conditions the mdrl gene may be activated by induction.
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Repeated exposure of tumour cell lines to cytotoxic agents can
lead to the development of sublines that are highly resistant to the
selecting agent. In several established cell lines. amplification ofa
specific gene has been found to be responsible for resistance
(Stark. 1986). However. selection for gene amplification is only
possible when the gene is active. Silent genes require transcrip-
tional activation before selection for amplification. The mdrl gene
encoding the multidrug resistance (MDR) protein. P-glycoprotein
(P-gp). belongs to this group of genes (Noonan et al. 1990). A
number ofMDR cell lines have shown increased expression ofthe
mdrl gene with little. ifany, gene amplification (Roninson. 1992).
Increased transcription may arise bv mutation (e.g. in genes
coding for regulatory proteins) or induction (reviewed in Borst.
1991). Development of resistance by induction demands the
continuous presence of drug. whereas drug resistance developed
by mutations occurs at random in both the presence and absence of
drug. Drug treatment subsequently selects the resistant cells and
their progony will dominate in recumrrng tumours as described by
Goldie and Coldman ( 1979).
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Several reports indicate that transcription ofthe mdrl gene can be
induced in cell lines. Thus. a varietv of environmental stresses and
circumstances that affect cellulardifferentiation have been shown to
induce m4drl gene expression (Chin et al. 1990a: Mickley et al.
1996). The anthracycline doxorubicin has been shown to induce
expression of P-gp after only 24 h of contact with sensitive cells
(Volm et al. 1991: Chevillard et al. 1992). The mdrl promoter has
been shown to respond directly to treatment with anthracyclines or
xinca alkaloids (Kohno et al. 1989). On the other hand. fluctuation
analysis expenrments have indicated that activation ofthe mdrl gene
in human sarcoma cells occurs as a result of a stochastic process
consistent with mutational events (Chen et al. 1994).
The purpose ofthe present study was: (1) to use Luria-Delbruck
fluctuation analysis to investigate whether daunorubicin (DNR)
induced P-gp in sensitive Ehrlich ascites tumour cells (EHR2) by
mutation or induction: (2) to investigate whether P-gp could be
induced in EHR2 by 24 h treatment in vivo with DNR: (3) to
investigate the expression ofP-gp after 24-h treatment m Xivo with
DNR in cells that are retreated after reversal ofresistance.
MATERIALS AND METHODS
Chemicals
Daunorubicin as hydrochloride w-as purchased from Farmitalia
Carlo Erba. Milan. Italy. All other chemicals were of analytical
grade.
11751176 DNielsenetal
Tumour cells
The murine Ehrlich ascites tumour cell line (EHR2) xas used in
the experiments. The cell line was maintained as ascites tumours
in mice by weekly transplantation of 1.5 x 10- cells per mouse and
established as an in Xitro culture.
The mice used xxere first-generation hybrids of female NRMI
and male inbred DBA/2 mice 18-22 g). The mice xxere bred at the
department. The study complied wxith the Danish and EU regula-
tions for animal wxelfare.
The tissue culture medium used was RPMI-1640 supplemented
with 10%7 fetal calf serum (FCS). L-glutamine (0.29 g 1-1). peni-
cillin (200 000 IU 1-1) and streptomycin (50 mg 1-1). The plating
efficiency of EHR2 was 65%7c. Exponentially growxing cells were
used for all experiments.
The rexertant EHR2/0.8/R was dexeloped from the resistant
EHR2/0.8 subline. This subline (EHR2/0.8) was maintained in
xivo bv intraperitoneal treatment with DNR 0.8 mc kg-' x 4
weekly corresponding to 50%7 of the LD dose (Nielsen et al.
1994). Compared with EHR2. EHR2/0.8 was highly resistant to
DNR (35-fold) and had increased expression ofP-gp (21-fold). To
develope EHR2/0.8/R. the treatment was discontinued after 54
passages (12 months) and the cell line was passaced for a further
60 passages (14 months) without treatment. Compared with
EHR2. EHRIJO.8/R was 2.4-fold resistant to DNR. A semiquan-
tification of P-gp with Western blot showed that P-gp expression
in EHR2/0.8/R xxas similar to the expression in EHR' (12 ± 3 and
12 ± 4 arbitrarv units respectixelv: Nielsen et al. 1994).
In vixvo induction of P-op in EHR' and EHR2/0.8/R cells
respectively was studied by treatment of the mice wvith DNR
6 mg kg'. on the 6th day oftransplantation. Investigation of these
cells was performed after 24 h of contact with DNR.
The resistant subline EHR2IDNR+ was used for calibration of
the Western blot assay and as a positixve control for immunocyto-
chemical analysis (Nielsen et al. 1994).
Determination of drug resistance
Growth inhibition was evaluated by the tetrazolium dye colorimetric
assay (MTT; 3-4-5-dimethyl-2-thiazolyl-2.5-diphenvl-2H-tetra-
zolium bromide: Tada et al. 1986). Production of formazan was
measured with a Multiscan MS ELISA reader(Labsystems. Finland).
The ICc,,. defined as the drug concentration that inhibited 50% of
formazan formation compared with controls. was determined directly
from semilogarithmic dose-response curves. Each expenrment was
repeated six times. Relative resistance was calculated as the ratio
betweenIC-,) ofthe resistant cell lines and IC.,, ofthe parental.
Determination of cellular proliferation
Cellular proliferation was measured as described by Chen et al
(1994). EHR2 cells and variant cells were seeded in 96 plates and
incubated for 72 h at 370C wxith 5% carbon dioxide. Cell growth
was estimated by the MYT colometric method (Tada et al. 1986).
Population doubling times (DT) were calculated according to the
equation DT = ( x 29. where AA, andA74s represent the
absorbance of the formazan product in variant cells and sensitive
EHR2 cells respectively. The doubling time ofEHR2 cells was 29 h.
Fluctuation analysis experiments
The Luria-Delbriick fluctuation analysis is a combined experi-
mental and statistical method that allows one to distinguish
Table 1 Fluctuation analysis of DNR-resistant Ehriich ascites tumour cells
14 days exposure to DNR 7.5 x 1-9 m
Plate no. Colonies per plate Positive well per plate
1 79 14 3 3
2 75 15 2 2
3 82 26 0 0
4 71 14 3 3
5 24 13 3 3
6 44 15 0 0
7 87 20 2 2
8 16 10 2 2
9 16 10 0 0
10 29 17 1 1
11 29 22 0 0
12 61 14 1 1
13 67 11 2 2
Mean colonies 52 15 1.5 1.5
Variance 712 22 1.4 1.4
Mutation rate
p calculatKona 4.1 x 10-- 1.2 x 10--
P.calculatioi$ NA- 1.4 x 10--
Luna-Delbruck fluctuabon analysis was performed by pre-expanding 13
populations of 2000 EHR2 cells then exposing the resuting cells to DNR for
14 days. Two weeks later, surviving clones were counted. aCalculated
according to Catcheside (1951). Caulated according to Luria-DelbrOck
(1943) as mnodified by Lea and Coulson (1949). cNot applicable, as the
methodology requires at least one population with no surviving colonies.
betmeen variant cells arising by rare spontaneous mutations and
xariant cells arising through adaption to an environmental selec-
tion (Lunra and Delbruck. 1943). The analysis is based on the
variation that is seen in the emergence of colonies from parallel
cultures. If resistance is acquired by induction via druc exposure.
the number of surviving colonies will be expected to haxe a
Poisson distribution. with the variance equal to the mean.
Thirteen tissue culture flasks (25 cm: Nunc A/S. Roskilde.
Denmark) were seeded with EHR2 cells (2000 cells per flask) and
allowed to grow (4.0 x lIW cells). Cells (2.6 x I0W) from each
population were then seeded into separate 24-well plates with
Nunc Tissue Culture Inserts (Anophore membranes: Nunc A/S)
(two plates per population). After 48 h of incubation to ensure
logarithmic growth. cells were treated with DNR 7.5 l-" si and
10- M respectivelv. The drug-containing medium w-as changed
every day for 14 days and then replaced by drug-free medium.
These selection conditions were chosen based on preliminary
expenments.
Surx-iving colonies were allowed to grow for 14 daxys and were
then individually harvested and propagated in drug-free medium
for further studies. In order to investigate the probabilitx of pre-
existing resistant clones in the original seeded population. popula-
tions of 2000 EHR2 cells were plated in separate 24-well plates
and treated directly with DNR (DNR 7.5 10` N and 10- sw: 26
plates per concentration) without expansion of the populations
before drug exposure. In this experiment. no survixinc colonies
were observed (data not shown).
Analysis of variance and mutation rates
The mutation rates were calculated according to the method of
Catcheside ( 1951 ) from the equation:
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Table 2 Resistance and P-glycoprotein expression in variants of EHR2 cells
selected by a single step for resistance with daunorubicin
Cells Doubling time (h) Fold resistanc P-gp (units,
rmen + s.e.m.)
EHR2 29 - 12±1
Varnants-
1BB5 27 3.8 16±3
2BC1 25 2.5 36 ± 5c
2BD5 29 3.3 17 ± 1
3BA1 29 2.9 19±1
3885 28 4.2 11 3
4AC1 25 4.8 9 3
5BB5 32 3.3 15 3
6AC3 29 2.6 30 3c
7BA1 27 5.2 7±2
8AD1 27 4.1 43± 7c
9AC1 33 4.8 22± 3c
9AD4 31 3.0 24+4
9AD5 31 3.5 11 3
9AB6 29 3.7 15 1
1OAB4 35 4.2 25 4c
11AC1 26 3.3 22 5
11AC2 29 3.5 31 3c
11AC4 29 3.8 10 2
11BC6 28 3.0 14 1
11BD6 29 3.7 12 3
12AC2 29 4.0 36 4c
12AD5 33 3.6 11 2
12BD4 30 3.1 33 5c
13AC3 27 3.4 26 5c
13BD4 29 3.1 18±4
aRelative resistance, ratio between the IC of variants and ICi of EHR2.
1BB5 is plate no. 1B (two plates per populabon), well no. B5. cSignificantty
different from the expression of P-p in EHR2, 3-6 experiments.
=2 In2(rJN, - r,/N,) gen-'
where is the mutation rate per cell generation. r is the number of
resistant colonies at time 1 and 2. N represents the initial number
of cells adjusted for plating efficiency and gen is the number of
generations. Furthermore. the PO method according to Luria and
Delbruck (1943) as modified by Lea and Coulson (1949) was
used:
= [(1n2)(-lnPf)JI(N
-N,,)
where PO represents the fraction of cultures with no mutants. i is
the rate ofmutations per cell generation and N, andNo are. respec-
tively. the final and the initial cell numbers. adjusted forthe plating
efficacy. As the last-mentioned method requires the presence of
cultures with no variant cells. it could not be used to calculate the
mutation rate in EHR2 cells exposed to DNR 7.5 10 m.
P-gp expression, Western blot analysis
Western blot analysis was used for semiquantification of P-gp
(Nielsen et al. 1994). Briefly. cells were suspended in hypotonic
buffer (sodium chloride 1O m-. magnesium chloride 6HW 0.15
nm-i. Tris 50 mn-i and phenylmethylsulphonylfluoride 2 mnst. pH
7.4). disrupted and centrifuged (4000g. 10 min). The supematants
were centrifuted at 40 000g for 60 min. The pellets were
harxested. diluted and centrifuged (40 000g. 60 mmn). The
membrane-enriched pellets were resuspended in buffer and loaded
on the gels.
Table 3 Expression of P-glycoprotein in revertant Ehrlich ascites tumour
cells after 24 h treatmnent in vivo with daunorubicin
P-glycoprotln
units (mean ± s.d.)
Day1 27±6(6)
Day 3 17 ± 1 (3)
Day7 38+±25(3)
Day 15 79 ± 21 (3)
Day 30 74± 20 (2)
Day 45 88 (1)
Day65 45(1)
Day120 47(1)
Day 240 46 (1)
Number of experiments given in parenthesis. two or three mice were used
for every experiment.
Following electrophoresis. proteins were transferred to nitro-
cellulose paper. The paper was blocked. incubated overnirht with
C219 (Centocor Diagnostics. Philadelphia. PA. USA). and for 2 h
with peroxidase-conjugated F(ab') fragments of affinity-purified
sheep anti-mouse IgG (Medac. Hamburg. Germany).
The expression of P-gp was determined by reflectance photo-
metrv. The relati've content ofP-gp was calculated using a standard
curve composed of membrane preparations with defined concen-
trations ofP-gp (Nielsen et al. 1994).
P-gp expression, immunocytochemical analysis
For immunocytochemistry the APAAP technique described by
Cordell et al (1984) was performed. Monolayers of cells on slides
were air dried and fixed in ice-cold methanol-acetone (1:1).
Incubation was performned overnight with C219 at 40C.
followed by incubation with rabbit antimouse IgG (Dako z259.
Copenhagen. Denmark) for 30 min at 24°C and then by incubation
with the (alkaline phosphatase anti-alkaline phosphatase) APAAP
complex (Dako D651) for 30 min at 24°C. The last two steps were
repeated for 10 min in order to amplify the signal. For washing
Tris-buffered saline (pH 7.6) was used. Fast red was used as
cromogen (Tablets. Kem-En-Tec. Copenhagen. Denmark).
RESULTS
Fluctuation analysis
The data presented in Table 1 show the number of surviving
colonies in the plates (two plates per population) from each group
studied by fluctuation analysis. In the group exposed to DNR
7.5 x 10-9xi. the mean number ofcolonies sur iving per plate was
52. with a variance of 712. In the group exposed to DNR lO' M.
the mean number of colonies surviving per plate was only 1.5.
with a variance equal to the mean.
Determination of mutation rates
Fluctuation analysis was also used to determine rates for DNR
resistance in the EHR2 clones. According to the method of
Catcheside (1951 ). the mutation rate was estimated to be 4.1 x I0o
at DNR 7.5 x 1X9M. whereas it decreased to 1.2 x l0-- at a drug
concentration of l0- mi.
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Drug resistance, expression of P-gp
A total of 25 clones were propagated from the group that was
treated with DNR 7.5 x 10-9 M. At least one clone from each popu-
lation was represented. All clones were stable. The resistance is
shown in Table 2. Compared with EHR2 the degree of resistance
varied from 2.5- to 5.2-fold (mean 3.6-fold). None of the resistant
clones manifested any significant difference in generation time.
Among the propagated clones 11 (44%) showed significantly
increased expression of P-gp as compared with EHR2 (Table 2).
Nineteen clones were isolated in the group that wastreated with
DNR 108 M; however, none of these clones could be propagated
for fturther studies.
Treabrment in vivo
Sensitive Ehrlich ascites tumour cells
Sensitive EHR2 cells were treated in vivo with DNR; 6 mg kg-'
for 24 h. The experiment was repeated five times using 2-3 mice
every time. The expression of P-gp in teated cells was mean
15 ±8 (s.d.) arbitrary units. The expression of P-gp in EHR2 has
previously been determined to be 12±4 units (Nielsen et al,
1994). In the present study, treatment with DNR for a short period
oftime in vivo did not induce P-gp in sensitive cells.
Revertant Ehrlich ascites tumour cells
EHR2/).8/R was treated in vivo with DNR 6 mg kg-' for 24 h. The
experiment was repeated six times using two or three mice every
time. The expressions of P-gp are given in Table 3. In three
instances the measurements were continued to day 15, in one
instance P-gp expression was followed to day 240. The cell lines
were passaged every seventh day in these periods. The expression
ofP-gp increased significantly in the treated tumours, showing the
highest expression from days 15 to 45. Immunocytochemistry
analysis was performed 1 day after treatment with DNR. This
analysis showed a uniform weak immunoreactivity of cytoplasma
and cell membrane of the EHR2/0.8/R cells, not different from
EHR2 cells. None of the EHR2/0.8/R cells showed significantly
increased expression of P-gp (data not shown).
The cytotoxicity of DNR was investigated immediately after
tratnent (day 1), the DNR-treated EHR2/0.8/R cells were
11.9-fold resistant compared with EHR2 and 4.9-fold resistant
compared with EHR210.8/R.
DISCUSSION
Knowledge regarding the genetic and biochemical nature of drug
resistance has been derived largely from cellular models devel-
oped by multistep, long-term drug exposure. Little is known about
the initial genetic changes and relative frequencies ofactivation of
various drug resistance mechanisms in tumour cell populations.
The theory of genetic instability of tumours suggested by Goldie
and Coldman (1979) proposes that drug-resistant cells emerge
from the clonal expansion of spontaneously mutated cells, rather
than from changes in cellular function induced by the drugs. This
theory is based on the classic fluctuation analysis experiments
performed by Luria and Delbrick (1943) in bacteria and by Law
(1952) in mammalian tumour cells. There are fumdamental genetic
differences between bacteria and somatic cells, specifically cancer
cells. In addition, considerable statistical error is associated with
the fluctuation analysis. The use and limitations of the analysis
have previously been reviewed by Kendal and Frost (1988). They
concluded that the method was appropriate in the field of somatic
cell genetics. However, reliable results were only found regarding
qualitative demonstration ofconsequences of variation.
After exposure to DNR 7.5 x 109 M the number of surviving
EHR2 clones arising from 13 different populations showed a
substantial fluctuation, as demonstrated in Table 1. The variance in
the number of colonies was 14-fold greater than the mean, indi-
catingthat, under these experimental conditions (5 log cell killing),
clonal survival of the cells was a consequence of the selection of
spontaneous mutations in the expanded cell populations.
The number of resistant colonies that arise in fluctuation
analysis is dependent on the rate of mutation, the generation time
of the variant cells and the time of appearance of the variant cells.
Moreover, the clones that are scored must arise during the expan-
sion ofthe parallel cultures (Kendal and Frost, 1988). Ifa resistant
cell was present in the initial seeding of 2000 EHR2 cells, at least
2048 progeny would have been present after 11 generations of
growth. The highest number of surviving colonies among our
expanded populations was 87, indicating that the event responsible
for the cell survival occurred after a minimum of five generations
of population expansion. Furthermore, the pre-existence of resis-
tant variants in the initial cell population was unlikely, as none of
the cell clones survived when the parental EHR2 cells were treated
with DNR without prior expansion.
Tlhe literature is generally unclear on the precise events regu-
lating the appearance of P-gp-mediated resistance. Both induction
and selection have been described, with no compelling evidence
prented to support definitively one or other mechanism as over-
riding in all cellularhumour models. Prior studies have been
performed in many different cells lines, using different drugs,
exposures and analytical approaches. It is possible that the various
conclusions apparent in the literature could reflect these different
experimental conditions. On the other hand, Chen et al (1994) used
fluctuation analysis to investigate the resistance mechanisms in
human sarcoma (MES-SA) cells exposed to the anthracycline
doxorubicin. In accordance with our result, these authors demon-
strated that spontaneous mutations conferred resistance to doxoru-
bicin. These authors also used the Luria and Delbriick fluctuation
analysis to investigate resistance mechanisms in MES-SA cells
exposed to paclitaxel (Dumontet et al, 1996), etoposide (Jaffrezou
et al, 1994) and a combination ofcyclosporin PSC 833 and doxoru-
bicin (Beketic-Oreskovic, 1995). In all instances except one,
analysis ofvariance supported the hypothesis ofspontaneous muta-
tions conferring resistance. In MES-SA cells exposed to a very
high dose of etoposide (5 piM), analysis of variance showed the
variance equal to the mean (Jaffrezou et al, 1994). This latter
finding was compatible with our finding in EHR2 cells exposed to
DNR 10 M, suggesting that at highly stringent conditions ofselec-
tion (6 log cell killing) the resistance could be a result ofadaption.
In the present study, the increase in P-gp was very modest;
further, P-gp increased in only 44% of the surviving clones. In
contrast, Chen et al (1994) in MES-SA cells exposed to doxoru-
bicin observed increased mRNA mdrl in all clones tested (Chen et
al, 1994). The expression of P-gp in these cells was, however,
modest, in accordance with our results (3-9% compared with
control, MDR cells). In addition, Dumontet et al (1996) demon-
strated increased rndrl mRNA in only 4 of 9 clones of MES-SA
clones exposed to paxlitaxel. Besides overexpression of the mdrl
gene, which is the predominant mechanism ofresistance to DNR.
cells can manifest resistance to this agent by decreased expression
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and/or altered activity of topoisomerase II. Other reported mecha-
nisms of resistance include alteration in cellular glutathione level.
expression of multidrug resistance-associated protein (MRP) or
expression oflung resistance protein (LRP) (Nielsen et al. 1996).
Compared with EHR2. the degree of resistance of the surviving
clones was modest (2.5 to 5.2-fold). This finding is in agreement
with the finding of Jaffrezou et al (1994). who used etoposide as
selecting arent. In the previously mentioned studies the degrees of
resistance were. however. found to be significantly higher (Chen et
al. 1994. Betetic-Oreskovic et al. 1995. Dumontet et al. 1996).
The rate ofmutation conferring resistance to DNR w-as 4.1 x 10-
per cell reneration. The statistical errors associated with variation
rate measurements are considerable (Kendal and Frost. 1988). On
the other hand. the mutation rate was in the range of spontaneous
point mutations described for mammalian cells (10--10- per cell
generation) (Borst. 1991) and comparable with that previously
described in human sarcoma (MES-SA) cells (Chen et al. 1994:
Jaffrezou et al. 1994. Dumontet et al. 1996: but lower than that
described for some gene amplifications. ranging from 1 to 7 x 10-'
per cell generation (Crawford et al. 1983. Tlsty et al. 1989).
In the present study. P-p could be induced in EHR2/0.8/R by
24 h treatment with DNR in vivo. but not in sensitive EHR2 cells.
The inducibility ofthe mdrl gene and P-gp by treatment with cyto-
statics has been investigated bv several authors (Kohno et al. 1989:
Chin et al. 1990b: Chaudharv and Roninson. 1993: Fardel et al.
1997). In contrast to our finding. P-gp could be induced in sensi-
tive cells. Kohno et al (1989) found that the mdrl promoter w-as
activated by vincristine. anthracyclines and colchicine. Chin et al
(1990b) demonstrated substantially increased mdrl mRNA in
rodent cell lines after acute cvtostatic treatment in vitro.
Chaudhary and Roninson (1993) reported significantly increased
mdrl gene expression and increased resistance (2- to 3-fold) in
several human tumour cell lines. which were exposed transiently
(12 h to 5 days) to chemotherapeutic drugs in vitro. Furthermore.
in L1210 tumour cells treated in vivo with doxorubicin 0.5 mg kg-'
for 10 min to 96 h. Volm et al (1991) measured the expression of
P-gp by immunohistochemistrv. They reported 85-90%c P-gp-posi-
tive cells 24 h after treatment. These authors. however. found only
a slirht increment in resistance. Recently. Chevillard et al (1992)
reported increased P-gp expression to be induced in sensitive
human lung adenocarcinoma cells (A549) after 24 h treatment
with doxorubicin. The emerguence of P-gp was followed by
approximately three-fold resistance to doxorubicin. P-gp has been
found to be dose dependently induced in a human pleural mesothe-
lioma xenograft (PXF 1118) (Licht et al. 1991). In this cell line.
P-gp was induced in absence of proliferation. thus favouring the
proposal that increased expression of P-gp is associated with
phenotypic cell change rather than resulting from selection of a
pre-existing drugy-resistant subpopulation.
In general the degree of resistance induced in sensitive cells
after transient treatment with cytostatic was low (2 to 3-fold)
(Licht et al. 1991. Volm et al. 1991: Chevillard et al. 1992). In
contrast. the EHR2/0.8/R cell line developed sig'nificant resistance
to DNR (11.9-fold). Previously. the expression ofP-gp in revertant
cell lines has only been investigated by Gekeler et al (1988). In an
actinomycin A-selected human leukaemia cell line maintained 1
month without selection pressure. mdrl gene transcription was
inducible after 72 h of retreatment. In this cell line the degree of
resistance was. how7ever. not investigated.
In the present study. immunocvtochemistrv showed a uniform
Aweak immunoreactivitv of the treated EHR20.8/R cells. not
significantly different from EHR2. The expression of P-gp was
probably below the detection himit of the immunocvtochemistrv
assay. Thus. this finding suggested that P-gp was induced in a high
fraction ofthe EHR2/0.8/R cells. In spite of cessation oftreatment
P-gp increased further after transplantation of EHR2/0.8/R.
reaching, the highest level from days 15-45. This high expression
of P-gp was comparable with the expression of P-gp in EHR2
cells. which had been exposed to multiple doses of DNR (Nielsen
et al. 1994). This finding could be in accordance with either a
direct activation ofthe mdrl promoter as described by Kohno et al
(1989) or an indirect activation ofthe promoter by interaction with
a regulatory protein (Gant et al. 1992). sugaesting that the activa-
tion ofthe mdrl gene occurred by induction.
In conclusion. our study demonstrates that P-gp expression and
DNR resistance are primarilv acquired by selection of sponta-
neously arising mutants. However. under certain conditions the
mdrl gene could be activated by induction.
ABBREVIATIONS
DNR. daunorubicin: MDR. multidrugy resistance: P-gp. P-glyco-
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